Table 1 Baseline characteristics for 65 NUP98 rearrangement AML patients receiving IC or VEN + HMA.
From: Adult AML with NUP98 rearrangements should be stratified into adverse-risk group
Different fusion proteins | |||||
|---|---|---|---|---|---|
Characteristic | Total n = 65 | NUP98::HOXA9 n = 29 | NUP98::NSD1 n = 20 | Others$ n = 16 | p value |
Age, years, Median [IQR] | 40.00 [30.00, 50.00] | 40.00 [30.00, 45.00] | 44.00 [38.50, 50.25] | 33.50 [27.00, 47.25] | 0.439 |
Gender, n (%) | 0.284 | ||||
Female | 30 (46.2) | 11 (37.9) | 9 (45.0) | 10 (62.5) | |
Male | 35 (53.8) | 18 (62.1) | 11 (55.0) | 6 (37.5) | |
Hematological parameters | |||||
WBC, ×109/L, Median [IQR] | 46.50 [7.12, 101.53] | 39.58 [6.27, 83.83] | 73.57 [10.02, 139.68] | 38.70 [12.81, 97.25] | 0.374 |
PLT,×109/L, Median [IQR] | 47.00 [30.00, 60.00] | 39.00 [26.50, 55.00] | 51.00 [43.25, 57.75] | 44.50 [29.75, 78.75] | 0.117 |
Hb, g/L, Median [IQR] | 80.00 [69.00, 97.00] | 75.00 [67.50, 88.00] | 81.00 [70.75, 96.00] | 91.00 [77.55, 103.75] | 0.228 |
Bone marrow blasts, %, Median [IQR] | 49.25 [28.38, 69.38] | 44.50 [25.50, 57.75] | 63.25 [47.88, 77.38] | 38.00 [20.75, 57.75] | 0.033 |
FAB Category, n (%) | <0.001 | ||||
M0 | 1 (1.5) | 1 (3.4) | 0 (0.0) | 0 (0.0) | |
M1 | 2 (3.1) | 1 (3.4) | 0 (0.0) | 1 (6.2) | |
M2 | 38 (58.5) | 24 (82.8) | 4 (20.0) | 10 (62.5) | |
M3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
M4 | 11 (16.9) | 3 (10.3) | 5 (25.0) | 3 (18.8) | |
M5 | 13 (20.0) | 0 (0.0) | 11 (55.0) | 2 (12.5) | |
M6 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
M7 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Chromosomal aberration, n (%) | |||||
Normal karyotype | 19 (29.2) | 2 (6.9) | 13 (65.0) | 4 (25.0) | <0.001 |
t(7;11) | 23 (35.4) | 21 (72.4) | 0 (0.0) | 2 (12.5) | <0.001 |
Abnormality11 | 9 (13.8) | 4 (13.8) | 0 (0.0) | 5 (31.2) | 0.026 |
Trisomy8 | 5 (7.7) | 2 (6.9) | 3 (15.0) | 0 (0.0) | 0.239 |
Complex karyotype | 7 (10.8) | 7 (24.1) | 0 (0.0) | 0 (0.0) | 0.008 |
Mutation, n (%) | |||||
FLT3-ITD | 22 (33.8) | 5 (17.2) | 13 (65.0) | 4 (25.0) | 0.002 |
WT1 | 19 (29.2) | 10 (34.5) | 4 (20.0) | 5 (31.2) | 0.537 |
NRAS | 12 (18.5) | 7 (24.1) | 1 (5.0) | 4 (25.0) | 0.175 |
KRAS | 12 (18.5) | 7 (24.1) | 1 (5.0) | 4 (25.0) | 0.175 |
TET2 | 11 (16.9) | 5 (17.2) | 3 (15.0) | 3 (18.8) | 0.955 |
RUNX1 | 8 (12.3) | 2 (6.9) | 2 (10.0) | 4 (25.0) | 0.195 |
PTPN11 | 7 (10.8) | 3 (10.3) | 1 (5.0) | 3 (18.8) | 0.415 |
CEBPA | 6 (9.2) | 2 (6.9) | 4 (20.0) | 0 (0.0) | 0.101 |
GATA2 | 4 (6.2) | 2 (6.9) | 0 (0.0) | 2 (12.5) | 0.293 |
NPM1 | 2 (3.1) | 0 (0.0) | 1 (5.0) | 1 (6.2) | 0.426 |
